NCT01030354

Brief Summary

This study will examine whether a higher protein meal replacement diet (consisting of 1 gram of protein per pound lean body mass) is more effective in causing weight loss compared to a standard meal replacement protein diet (consisting of ½ gram of protein per pound of lean body mass). The study will assign approximately 100 subjects (50 each) to the following arms 1) higher meal replacement diet program 2) standard meal replacement diet program. All participants will meet with a registered dietitian to provide nutrition education and behavior modification, including general exercise recommendations. As part of your participation, you must be willing to undergo a measurement of body fat, and blood tests, and be willing to use Herbalife Meal replacements as part of your diet for the duration of the study (one year).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jul 2004

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2004

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2005

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2005

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

December 10, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 11, 2009

Completed
Last Updated

May 25, 2025

Status Verified

May 1, 2025

Enrollment Period

1 year

First QC Date

December 10, 2009

Last Update Submit

May 22, 2025

Conditions

Keywords

SatietyMeal ReplacementsHigh ProteinStandard Protein

Outcome Measures

Primary Outcomes (1)

  • The primary efficacy endpoint is the change in weight.

    Baseline, 3, 6 and 12 months

Secondary Outcomes (1)

  • Secondary endpoints are changes in fasting plasma glucose levels associated with weight loss, insulin, blood pressure, lipid levels and body fat.

    Baseline and 12 months

Study Arms (2)

Dietary Intervention and Higher protein meal replacement

ACTIVE COMPARATOR

A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass

Dietary Supplement: Herbalife Meal Replacements

Dietary Intervention and Standard Protein Meal Replacement

ACTIVE COMPARATOR

Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass

Dietary Supplement: Herbalife Meal Replacements

Interventions

Herbalife Meal ReplacementsDIETARY_SUPPLEMENT

Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass

Dietary Intervention and Higher protein meal replacementDietary Intervention and Standard Protein Meal Replacement

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 30 years and older at screening
  • Female subjects must have a negative pregnancy test at screening, must be surgically sterile or at least 6 months postmenopausal or must use a form of birth control measure. Hormonal birth control, IUD, or abstinence will be acceptable as birth control measures. Other types of birth controls such as condom, diaphragm, or sponges may not be considered adequate forms of birth control measures in this study.
  • BMI of 27 to 40 kg/m2 inclusive.
  • Subjects must be in good health as determined by medical history, physical examination, and screening clinical laboratory including chemistry panel and CBC.
  • h. Must have stable smoking habits (or be non-smokers) for at least 6 months prior to screening and agree not to intend to change such habits during the course of the study.
  • i. Subjects requiring the regular use of any prescription medication may be admitted to the study providing the dose is stable.
  • j. Ethical
  • Subject must sign the Institutional Review Board-approved written informed consent prior to he initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.

You may not qualify if:

  • Weight Stability. Any subject who reports weight change of \> 3.0 kg in the month prior to screening.
  • Any subject who has been on a very low calorie diet ( \< 800 kcal/day) for a period of 4 months or more in the 12 months prior to screening, or who has lost \> 10 kg in the 6 months prior to screening.
  • Use of any other investigational drug (s) within 8 weeks prior to screening.
  • Abnormal laboratory parameters: Serum creatinine \> 1.6 mg/dl, Liver function tests, ALT, AST, Bili results \> 2.0 times the upper limit of normal. Triglycerides \> 500 mg/dl, total cholesterol \> 350 mg/dl, TSH outside of normal range.
  • Subjects who drink more than 1 alcoholic beverages per day.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

Related Publications (1)

  • Li Z, Treyzon L, Chen S, Yan E, Thames G, Carpenter CL. Protein-enriched meal replacements do not adversely affect liver, kidney or bone density: an outpatient randomized controlled trial. Nutr J. 2010 Dec 31;9:72. doi: 10.1186/1475-2891-9-72.

MeSH Terms

Conditions

Weight LossObesity

Condition Hierarchy (Ancestors)

Body Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsOverweightOvernutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Zhaoping Li, MD, PhD

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 10, 2009

First Posted

December 11, 2009

Study Start

July 1, 2004

Primary Completion

July 1, 2005

Study Completion

December 1, 2005

Last Updated

May 25, 2025

Record last verified: 2025-05

Locations